Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has a beta value of 0.54 and has seen 1.64 million shares traded in the last trading session. The company, currently valued at $2.25B, closed the last trade at $17.54 per share which meant it lost -$0.01 on the day or -0.06% during that session. The AUPH stock price is -16.88% off its 52-week high price of $20.50 and 44.58% above the 52-week low of $9.72. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.1 million shares traded. The 3-month trading volume is 3.70 million shares.
The consensus among analysts is that Aurinia Pharmaceuticals Inc. (AUPH) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 9 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.14.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) trade information
Sporting -0.06% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the AUPH stock price touched $17.54 or saw a rise of 3.2%. Year-to-date, Aurinia Pharmaceuticals Inc. shares have moved 26.83%, while the 5-day performance has seen it change -0.90%. Over the past 30 days, the shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) have changed 49.79%. Short interest in the company has seen 12.83 million shares shorted with days to cover at 2.45.
Wall Street analysts have a consensus price target for the stock at $28.33, which means that the shares’ value could jump 38.09% from current levels. The projected low price target is $15.00 while the price target rests at a high of $35.00. In that case, then, we find that the current price level is -99.54% off the targeted high while a plunge would see the stock lose 14.48% from current levels.
Aurinia Pharmaceuticals Inc. (AUPH) estimates and forecasts
Figures show that Aurinia Pharmaceuticals Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 37.89% over the past 6 months, with this year growth rate of -54.02%, compared to 18.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 36.40% and 81.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 142.80%.
5 analysts offering their estimates for the company have set an average revenue estimate of $40k for the current quarter. 3 have an estimated revenue figure of $20k for the next quarter concluding in Mar 2018. Year-ago sales stood $30k and $31k respectively for this quarter and the next, and analysts expect sales will grow by 33.30% for the current quarter and -35.50% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -8.40% over the past 5 years.
Aurinia Pharmaceuticals Inc. is expected to release its next earnings report between November 08 and November 12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s Major holders
Insiders own 8.02% of the company shares, while shares held by institutions stand at 46.85% with a share float percentage of 50.93%. Investors are also buoyed by the number of investors in a company, with Aurinia Pharmaceuticals Inc. having a total of 234 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 9.31 million shares worth more than $120.9 million. As of Mar 30, 2021, FMR, LLC held 7.26% of shares outstanding.
The other major institutional holder is Orbimed Advisors LLC., with the holding of over 6.07 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $78.81 million and represent 4.74% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Advisor Biotechnology Fund and Fidelity Select Portfolios – Biotechnology. As of Apr 29, 2021, the former fund manager holds about 1.53% shares in the company for having 1.97 million shares of worth $26.1 million while later fund manager owns 1.5 million shares of worth $19.85 million as of Apr 29, 2021, which makes it owner of about 1.17% of company’s outstanding stock.